Skip to content

Inspection Record

GlaxoSmithKline Vaccines Srl — FDA 483 Findings

US FDAInspected 2024-01-26Published 2026-10-20 5 findingsLaboratory and QC controlsDeviation, CAPA, and investigationTraining and personnelQuality unit oversightOther quality system

Inspectors Roger F ZabinskiThe inspectors who signed the published document.Inspector lookup

View the regulator's official source The source document is always the basis for judgement.

Findings

1Laboratory and QC controls

Established laboratory control mechanisms are not followed.

2Deviation, CAPA, and investigation

There is a failure to thoroughly review any unexplained discrepancy and the failure of a batch or any of its components to meet any of its specifications whether or not the batch has been already distributed.

3Training and personnel

Employees engaged in the manufacture and processing of a drug product lack the training required to perform their assigned functions.

4Quality unit oversight

The responsibilities and procedures applicable to the quality control unit are not fully followed.

5Other quality system

Not all adverse drug experiences that are both serious and unexpected have been reported to FDA within 15 calendar days of initial receipt of the information.

Similar findings at other companies

GRM selected findings from the same type of public document whose wording is close to a finding in this document. One per company.

A record as of the US FDA document published on 2026-10-20. Check the agency's announcements for any later corrective action, and rely on the original text. Translation and classification are machine-made.

GlaxoSmithKline Vaccines Srl company profile — full historyAll US FDA findings US FDA documents, 2026 Go to Findings search
Linked from (backlinks)
Briefs that featured this document
Weekly Newsletter

Get new findings like these every Monday

Every Monday we email the week's new findings and actions from the FDA, EMA, Health Canada and MFDS. Each one links to its record on our site, where you'll find the regulator's original document. We'll also let you know when the site gains new features. Unsubscribe any time with one click.

See recent findings first

Sent every Monday · a confirmation email follows when you subscribe · unsubscribe from the footer of any email.